CoChat

High-Throughput Screening Using iPSC-Derived Neuronal Progenitors to Identify Compounds Counteracting Epigenetic Gene Silencing in Fragile X Syndrome

Open access
Kaufmann, Markus, Schuffenhauer, Ansgar, Fruh, Isabelle, Klein, Jessica, Thiemeyer, Anke, Rigo, Pierre, Gomez-Mancilla, Baltazar, Heidinger-Millot, Valerie, Bouwmeester, Tewis, Schopfer, Ulrich, Mueller, Matthias, Fodor, Barna D., Cobos-Correa, Amanda · 2015 · SLAS DISCOVERY

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

Fragile X syndrome (FXS) is the most common form of inherited mental retardation, and it is caused in most of cases by epigenetic silencing of the Fmr1 gene. Today, no specific therapy exists for FXS, and current treatments are only directed to improve behavioral symptoms. Neuronal progenitors derived from FXS patient induced pluripotent stem cells (iPSCs) represent a unique model to study the disease and develop assays for large-scale drug discovery screens since they conserve the Fmr1 gene silenced within the disease context. We have established a high-content imaging assay to run a large-scale phenotypic screen aimed to identify compounds that reactivate the silenced Fmr1 gene. A set of 50,000 compounds was tested, including modulators of several epigenetic targets. We describe an integrated drug discovery model comprising iPSC generation, culture scale-up, and quality control and screening with a very sensitive high-content imaging assay assisted by single-cell image analysis and multiparametric data analysis based on machine learning algorithms. The screening identified several compounds that induced a weak expression of fragile X mental retardation protein (FMRP) and thus sets the basis for further large-scale screens to find candidate drugs or targets tackling the underlying mechanism of FXS with potential for therapeutic intervention.

Overview

Integrity signals

Registry

Crossref · 10.1177/1087057115588287

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Cited by

See all 97

Metadata

Authors
Kaufmann, M., Schuffenhauer, A., Fruh, I., Klein, J., Thiemeyer, A., Rigo, P., Gomez-Mancilla, B., Heidinger-Millot, V., Bouwmeester, T., Schopfer, U., Mueller, M., Fodor, B. D., & Cobos-Correa, A.
Affiliations
Novartis (Switzerland) (CH)
Venue
SLAS DISCOVERY
Publisher
Elsevier BV
Published
2015-10
Volume
20
Issue
9
Pages
1101-1111
ISSN
2472-5552 (ISSN-L)
OpenAlex
W1875301382
Cited by
87
References
30
Citations by year
2026: 3 · 2025: 3 · 2024: 1 · 2023: 3 · 2022: 7 · 2021: 8 · 2020: 9 · 2019: 9 · 2018: 14 · 2017: 8 · 2016: 19 · 2015: 2
FWCI
9.79
Type
journal article
Language
en
Open access
Licence
Locations
  • SLAS DISCOVERY (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
Keywords
fragile X syndrome, FMR1 gene silencing, epigenetic silencing, induced pluripotent stem cells, neuronal precursors, phenotypic screening, epigenetic regulators, drug discovery, machine learning, single-cell image analysis
MeSH terms
Cells, Cultured, Drug Evaluation, Preclinical, Fragile X Syndrome, Humans, Trinucleotide Repeats, Gene Silencing, Fragile X Messenger Ribonucleoprotein 1, Induced Pluripotent Stem Cells, High-Throughput Screening Assays, Neural Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High-Throughput Screening Using iPSC-Derived Neuronal Progenitors to Identify Compounds Counteracting Epigenetic Gene Silencing in Fragile X Syndrome. https://app.cochat.ai/papers/10.1177/1087057115588287
The paper
Kaufmann, M., Schuffenhauer, A., Fruh, I., Klein, J., Thiemeyer, A., Rigo, P., Gomez-Mancilla, B., Heidinger-Millot, V., Bouwmeester, T., Schopfer, U., Mueller, M., Fodor, B. D., & Cobos-Correa, A. (2015). High-Throughput Screening Using iPSC-Derived Neuronal Progenitors to Identify Compounds Counteracting Epigenetic Gene Silencing in Fragile X Syndrome. SLAS DISCOVERY. https://doi.org/10.1177/1087057115588287

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.